Zacks Investment Research upgraded shares of DBV Technologies S.A. (NASDAQ:DBVT) from a sell rating to a hold rating in a research note published on Tuesday. Zacks Investment Research currently has $49.00 price target on the stock.

According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “

Several other research firms have also weighed in on DBVT. BidaskClub upgraded DBV Technologies from a hold rating to a buy rating in a report on Tuesday, July 25th. Morgan Stanley restated an overweight rating on shares of DBV Technologies in a report on Monday, July 10th. Jefferies Group LLC restated a buy rating and issued a $47.00 target price on shares of DBV Technologies in a report on Thursday, June 1st. ValuEngine lowered DBV Technologies from a hold rating to a sell rating in a report on Friday, June 30th. Finally, Deutsche Bank AG started coverage on DBV Technologies in a report on Friday, June 23rd. They issued a buy rating and a $46.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. DBV Technologies has an average rating of Buy and an average target price of $48.83.

DBV Technologies (NASDAQ:DBVT) traded down 0.26% during mid-day trading on Tuesday, hitting $45.53. 73,453 shares of the stock were exchanged. DBV Technologies has a one year low of $31.87 and a one year high of $45.70. The company has a 50-day moving average price of $38.47 and a 200-day moving average price of $35.58. The company’s market cap is $2.09 billion.

TRADEMARK VIOLATION NOTICE: “DBV Technologies S.A. (NASDAQ:DBVT) Upgraded to Hold at Zacks Investment Research” was reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/05/dbv-technologies-s-a-nasdaqdbvt-upgraded-to-hold-at-zacks-investment-research.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. increased its position in shares of DBV Technologies by 3.1% in the first quarter. Goldman Sachs Group Inc. now owns 55,499 shares of the company’s stock valued at $1,955,000 after buying an additional 1,647 shares in the last quarter. Alps Advisors Inc. increased its position in shares of DBV Technologies by 4.9% in the second quarter. Alps Advisors Inc. now owns 43,513 shares of the company’s stock valued at $1,554,000 after buying an additional 2,040 shares in the last quarter. Parametric Portfolio Associates LLC increased its position in shares of DBV Technologies by 9.2% in the first quarter. Parametric Portfolio Associates LLC now owns 33,270 shares of the company’s stock valued at $1,172,000 after buying an additional 2,794 shares in the last quarter. Jennison Associates LLC increased its position in shares of DBV Technologies by 0.7% in the first quarter. Jennison Associates LLC now owns 537,726 shares of the company’s stock valued at $18,939,000 after buying an additional 3,577 shares in the last quarter. Finally, Emory University increased its position in shares of DBV Technologies by 7.9% in the first quarter. Emory University now owns 62,884 shares of the company’s stock valued at $2,215,000 after buying an additional 4,628 shares in the last quarter. 48.25% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Get a free copy of the Zacks research report on DBV Technologies (DBVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.